These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 19297519)

  • 21. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic epidemiology of pharmacogenetic variations in CYP2C9, CYP4F2 and VKORC1 genes associated with warfarin dosage in the Indian population.
    Giri AK; Khan NM; Grover S; Kaur I; Basu A; Tandon N; Scaria V; ; ; Kukreti R; Brahmachari SK; Bharadwaj D
    Pharmacogenomics; 2014 Jul; 15(10):1337-54. PubMed ID: 25155935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of CYP4F2 polymorphism on response to warfarin during induction phase: a prospective, open-label, observational cohort study.
    Bejarano-Achache I; Levy L; Mlynarsky L; Bialer M; Muszkat M; Caraco Y
    Clin Ther; 2012 Apr; 34(4):811-23. PubMed ID: 22417713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
    Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
    J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
    Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
    PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of warfarin related genes and non- genetic factors on administrative dose in Shanghai area].
    Zhuang W; Wu D; Wang Z
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jan; 35(1):13-7. PubMed ID: 24602724
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes.
    Teichert M; Eijgelsheim M; Uitterlinden AG; Buhre PN; Hofman A; De Smet PA; Visser LE; Stricker BH
    Pharmacogenet Genomics; 2011 Jan; 21(1):26-34. PubMed ID: 21063236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.
    Cha PC; Mushiroda T; Takahashi A; Kubo M; Minami S; Kamatani N; Nakamura Y
    Hum Mol Genet; 2010 Dec; 19(23):4735-44. PubMed ID: 20833655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.
    Danese E; Montagnana M; Johnson JA; Rettie AE; Zambon CF; Lubitz SA; Suarez-Kurtz G; Cavallari LH; Zhao L; Huang M; Nakamura Y; Mushiroda T; Kringen MK; Borgiani P; Ciccacci C; Au NT; Langaee T; Siguret V; Loriot MA; Sagreiya H; Altman RB; Shahin MH; Scott SA; Khalifa SI; Chowbay B; Suriapranata IM; Teichert M; Stricker BH; Taljaard M; Botton MR; Zhang JE; Pirmohamed M; Zhang X; Carlquist JF; Horne BD; Lee MT; Pengo V; Guidi GC; Minuz P; Fava C
    Clin Pharmacol Ther; 2012 Dec; 92(6):746-56. PubMed ID: 23132553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
    Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
    Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simple, sensitive, and high-throughput LC-APCI-MS/MS method for simultaneous determination of vitamin K
    Hu K; Li Y; Ding R; Zhai Y; Chen L; Qian W; Yang J
    J Pharm Biomed Anal; 2018 Sep; 159():82-91. PubMed ID: 29980023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
    Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
    Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of novel CYP4F2 and VKORC1 coding region DNA variants in patients requiring high warfarin doses.
    Burmester JK; Berg RL; Glurich I; Yale SH; Schmelzer JR; Caldwell MD
    Clin Med Res; 2011 Nov; 9(3-4):119-24. PubMed ID: 21562135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.
    Tan SL; Li Z; Zhang W; Song GB; Liu LM; Peng J; Liu ZQ; Fan L; Meng XG; Wang LS; Chen Y; Zhou XM; Zhou HH
    Eur J Clin Pharmacol; 2013 Oct; 69(10):1769-75. PubMed ID: 23949431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplex pyrosequencing method to determine CYP2C9*3, VKORC1*2, and CYP4F2*3 polymorphisms simultaneously: its application to a Korean population and comparisons with other ethnic groups.
    Kim KA; Song WG; Lee HM; Joo HJ; Park JY
    Mol Biol Rep; 2014 Nov; 41(11):7305-12. PubMed ID: 25069408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Ketoconazole, a CYP4F2 Inhibitor, and CYP4F2*3 Genetic Polymorphism on Pharmacokinetics of Vitamin K
    Park JW; Kim KA; Park JY
    J Clin Pharmacol; 2019 Nov; 59(11):1453-1461. PubMed ID: 31134657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.